Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonmyeloablative allogeneic stem cell transplant for the treatment of hematologic disorders

Trial Profile

Nonmyeloablative allogeneic stem cell transplant for the treatment of hematologic disorders

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Granulocyte colony-stimulating factors (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Methotrexate
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological disorders; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms MINI-HEME
  • Most Recent Events

    • 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top